Other — Enhancing pancreatic cancer ablation efficiency: bipolar IRE with conductive MOF

6 measurement groups · 11 results

Reported values remain attached to the sample, method, conditions, extraction quality and source location that produced them.

Ni3(HITP)2@PDA nanoparticles · Powder

KPC/L929 cell viability after 12 and 24 h exposure and blood haemolysis at nanoparticle concentrations up to 200 ug/mL.

Temperature: 310
Atmosphere: cell/blood assay
Context: Composite sample biosafety.
Measurement source: 2023 · 3.4 Biosafety of Ni3(HITP)2@PDA · Fig. 3; Fig. S16

Property	Reported value	Normalised value	Uncertainty	Origin and quality	Source
No significant cytotoxicity below 100 ug/mL	no significant cytotoxicity at concentrations below 100 ug mL^-1 (P > 0.05)	—	threshold	Text Qualitative	2023 · 3.4 Biosafety · Fig. 3a; Fig. S16a
Haemolysis below 3% under 200 ug/mL	hemolysis rate below 3% at concentrations under 200 ug mL^-1	—	upper bound	Text Approximate	2023 · 3.4 Biosafety · Fig. 3b; Fig. S16b

Ni3(HITP)2@PDA nanoparticles · Powder

PDI and hydrodynamic size measurement of pristine Ni3(HITP)2 and Ni3(HITP)2@PDA.

Atmosphere: solution
Context: Pristine versus PDA-modified particles.
Measurement source: 2022 · 3.3 Characterization of conductive MOF · Fig. 2h; Fig. S11

Property	Reported value	Normalised value	Uncertainty	Origin and quality	Source
Ni3(HITP)2@PDA particle diameter	426.90 +/- 7.18 nm	—	+/- 7.18 nm	Text Exact Reported	2022 · 3.3 Characterization of conductive MOF · Fig. 2h
Ni3(HITP)2@PDA PDIMarked as a best value within this paper	0.4318 +/- 0.02	—	+/- 0.02	Text Exact Reported	2022 · 3.3 Characterization of conductive MOF · Fig. S11
Pristine Ni3(HITP)2 PDI	0.4878 +/- 0.04	—	+/- 0.04	Text Exact Reported	2022 · 3.3 Characterization of conductive MOF · Fig. S11

Bipolar IRE + Ni3(HITP)2@PDA treated KPC/tumour model · Model

KPC cell apoptosis after monopolar, bipolar, and bipolar + Ni3(HITP)2@PDA IRE treatments.

Atmosphere: cell culture
Geometry: Monopolar 1500 V cm^-1, 90 us, 90 pulses; bipolar 2500 V cm^-1, 90 us, 90 pulses.
Context: Application model with conductive MOF composite.
Measurement source: 2025-2026 · 3.5 In vitro therapeutic mechanism · Fig. 4b; Fig. S19

Property	Reported value	Normalised value	Uncertainty	Origin and quality	Source
Bipolar IRE apoptosis rate	45.52 +/- 1.83%	—	+/- 1.83%	Text Exact Reported	2025 · 3.5 In vitro therapeutic mechanism · Fig. 4b; Fig. S19
Bipolar IRE + Ni3(HITP)2@PDA apoptosis rateMarked as a best value within this paper	59.95 +/- 2.41%	—	+/- 2.41%	Text Exact Reported	2025 · 3.5 In vitro therapeutic mechanism · Fig. 4b; Fig. S19

Bipolar IRE + Ni3(HITP)2@PDA treated KPC/tumour model · Model

Tumour volume, tumour weight, body weight and histology over 14 days after bipolar IRE with local Ni3(HITP)2@PDA injection.

Atmosphere: in vivo
Geometry: 100 uL Ni3(HITP)2@PDA injected 2 h before bipolar IRE; 2500 V cm^-1, 90 us, 90 pulses.
Context: Application model with conductive MOF composite.
Measurement source: 2025-2027 · 3.6 In vivo therapeutic efficacy · Fig. 5; Fig. S20-S22

Property	Reported value	Normalised value	Uncertainty	Origin and quality	Source
Body weight stability during 14-day in vivo study	Body weight remained stable across all groups, with no significant differences	—	—	Text Qualitative	2025 · 3.6 In vivo therapeutic efficacy · Fig. 5c
In vivo tumour-volume reductionMarked as a best value within this paper	85.77% +/- 0.21 reduction in tumor volume	—	+/- 0.21%	Text Exact Reported	2025 · 3.6 In vivo therapeutic efficacy · Fig. 5b; Fig. S20

Bipolar IRE + Ni3(HITP)2@PDA treated KPC/tumour model · Model

Bipolar electrode ablation zone at 2500 V cm^-1 measured 24 h post-experiment.

Geometry: Bipolar and monopolar electrodes inserted along potato length; minimum insertion depth 10 mm.
Context: Application model; electrode ablation benchmark.
Measurement source: 2022 · 3.2 In vitro therapeutic efficacy · Fig. S6

Property	Reported value	Normalised value	Uncertainty	Origin and quality	Source
Bipolar-electrode potato ablation area at 2500 V cm^-1	2.88 +/- 0.08 cm2	—	+/- 0.08 cm2	Text Exact Reported	2022 · 3.2 In vitro therapeutic efficacy · Fig. S6

Ni3(HITP)2@PDA nanoparticles · Powder

Solution stability assessment of Ni3(HITP)2@PDA.

Atmosphere: solution
Context: Composite sample.
Measurement source: 2022 · 3.3 Characterization of conductive MOF · Fig. S13

Property	Reported value	Normalised value	Uncertainty	Origin and quality	Source
Ni3(HITP)2@PDA zeta potential	-31.71 +/- 2.75 mV	—	+/- 2.75 mV	Text Exact Reported	2022 · 3.3 Characterization of conductive MOF · Fig. S13